

Pietro Ravani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/944608/publications.pdf>

Version: 2024-02-01

236
papers

12,810
citations

19608

61
h-index

29081

104
g-index

244
all docs

244
docs citations

244
times ranked

13115
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality and Resource Use Among Individuals With Chronic Kidney Disease or Cancer in Alberta, Canada, 2004-2015. <i>JAMA Network Open</i> , 2022, 5, e2144713.	2.8	8
2	Risks of Changing Estimated Glomerular Filtration Rate Thresholds in Older Personsâ€”Reply. <i>JAMA Internal Medicine</i> , 2022, 182, 239.	2.6	2
3	A pilot randomised controlled trial of an energy management programme for adults on maintenance haemodialysis: the fatigue-HD study. <i>BMJ Open</i> , 2022, 12, e051475.	0.8	3
4	Location, Location, Location: Usual Source of Care, Kidney Disease Outcomes, and the Social Determinants of Health. <i>Kidney Medicine</i> , 2022, 4, 100430.	1.0	0
5	The availability of support and peritoneal dialysis survival: A cohort study. <i>Peritoneal Dialysis International</i> , 2022, , 089686082210867.	1.1	1
6	Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease. <i>Kidney International</i> , 2022, 101, 1260-1270.	2.6	6
7	Development and External Validation of a Machine Learning Model for Progression of CKD. <i>Kidney International Reports</i> , 2022, 7, 1772-1781.	0.4	15
8	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
9	Immunosuppressive therapy for IgA nephropathy in children. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
10	Reply to: â€œOn the Importance of Considering Glycosylation when Evaluating Biologicsâ€” <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, ASN.2022050534.	3.0	0
11	Sex differences in the vascular access of hemodialysis patients: a cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1412-1418.	1.4	6
12	The Association Between Estimated Glomerular Filtration Rate and Hospitalization for Fatigue: A Population-Based Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110012.	0.6	1
13	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2021, 2249, 125-165.	0.4	0
14	Association Between Attempted Arteriovenous Fistula Creation and Mortality in People Starting Hemodialysis via a Catheter: A Multicenter, Retrospective Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110328.	0.6	4
15	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 972-982.	3.0	103
16	In-center nocturnal hemodialysis improves health-related quality of life for patients with end-stage renal disease. <i>Journal of Nephrology</i> , 2021, , 1.	0.9	5
17	Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease. <i>JAMA Network Open</i> , 2021, 4, e219225.	2.8	18
18	Progression and Regression of Chronic Kidney Disease by Age Among Adults in a Population-Based Cohort in Alberta, Canada. <i>JAMA Network Open</i> , 2021, 4, e2112828.	2.8	41

#	ARTICLE	IF	CITATIONS
19	Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults. <i>JAMA Pediatrics</i> , 2021, 175, 631.	3.3	21
20	NSAID prescriptions in kidney transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14405.	0.8	7
21	Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study. <i>Transplantation Direct</i> , 2021, 7, e736.	0.8	3
22	Inadequate Dosage of Mycophenolate Mofetil Is Likely to Yield Substandard Trial Results and Substandard Patient Care—Reply. <i>JAMA Pediatrics</i> , 2021, 175, 870.	3.3	0
23	Accounting for Age in the Definition of Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1359.	2.6	70
24	Training clinicians in a problem-solving fatigue programme for patients receiving maintenance haemodialysis. <i>Journal of Renal Care</i> , 2021, , .	0.6	1
25	Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2652-2663.	3.0	30
26	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 1-16.	0.4	1
27	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 103-124.	0.4	1
28	Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol. <i>BMJ Open</i> , 2021, 11, e052450.	0.8	5
29	Secular Changes in Mortality and Hospitalization over Time in People with Kidney Failure or Severe CKD as Compared with Other Noncommunicable Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2631-2641.	3.0	1
30	Graft Function, Albuminuria, and the Risk of Hemorrhage and Thrombosis After Kidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095219.	0.6	3
31	Nephrology consultation and kidney failure in people with stage 4 chronic kidney disease: a population-based cohort study. <i>Journal of Nephrology</i> , 2020, 34, 1225-1234.	0.9	3
32	Four steps to standardize reporting of peritoneal dialysis technique failure: A proposed approach. <i>Peritoneal Dialysis International</i> , 2020, , 089686082097693.	1.1	3
33	Association of Age With Risk of Kidney Failure in Adults With Stage IV Chronic Kidney Disease in Canada. <i>JAMA Network Open</i> , 2020, 3, e2017150.	2.8	26
34	Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096406.	0.6	1
35	Investigating the Relationship Between Age and Kidney Failure in Adults With Category 4 Chronic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096681.	0.6	4
36	COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. <i>CMAJ Open</i> , 2020, 8, E887-E894.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Association Between Attempted Arteriovenous Fistula Creation and Mortality in Patients Starting Hemodialysis Via a Catheter: A Multicenter, Canadian, Retrospective Cohort Study. <i>Journal of Vascular Surgery</i> , 2020, 72, e354-e355.	0.6	0
38	Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 591-601.	3.0	55
39	Changes in kidney function follow living donor nephrectomy. <i>Kidney International</i> , 2020, 98, 176-186.	2.6	41
40	Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. <i>Pediatric Nephrology</i> , 2020, 35, 1437-1444.	0.9	22
41	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 2020, CD012466.	1.5	7
42	Association of Initiation of Dialysis With Hospital Length of Stay and Intensity of Care in Older Adults With Kidney Failure. <i>JAMA Network Open</i> , 2020, 3, e200222.	2.8	14
43	Quantifying the risk of insertion-related peritoneal dialysis catheter complications following laparoscopic placement: Results from the North American PD Catheter Registry. <i>Peritoneal Dialysis International</i> , 2020, 40, 185-192.	1.1	15
44	Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. <i>Pediatric Nephrology</i> , 2020, 35, 997-1003.	0.9	19
45	Mortality and Morbidity in Kidney Transplant Recipients With a Failing Graft: A Matched Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812090867.	0.6	17
46	Outcomes of the First and Second Hemodialysis Fistula: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 62-71.	2.1	15
47	Timing of Fistula Creation and the Probability of Catheter-Free Use: A Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811984313.	0.6	5
48	Nephrology consultation and mortality in people with stage 4 chronic kidney disease: a population-based study. <i>Cmaj</i> , 2019, 191, E274-E282.	0.9	15
49	Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. <i>JAMA Network Open</i> , 2019, 2, e191795.	2.8	73
50	Outcomes Following Macrolide Use in Kidney Transplant Recipients. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811983070.	0.6	9
51	The Influence of Age on the Likelihood of Catheter-Free Fistula Use in Hemodialysis Patients. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811986194.	0.6	6
52	Protocol for a pilot randomised controlled trial of an educational programme for adults on chronic haemodialysis with fatigue (Fatigue-HD). <i>BMJ Open</i> , 2019, 9, e030333.	0.8	9
53	Influence of Mortality on Estimating the Risk of Kidney Failure in People with Stage 4 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2219-2227.	3.0	37
54	Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 467-475.	2.1	73

#	ARTICLE	IF	CITATIONS
55	Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e029232.	0.8	11
56	Association between Duration of Predialysis Care and Mortality after Dialysis Start. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 893-899.	2.2	6
57	Report of the Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	2.1	62
58	Adverse events linked with the use of chimeric and humanized antiâ€“CD20 antibodies in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1238-1249.	1.1	46
59	Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 429-435.	2.2	11
60	Controversies in vascular access. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 209-213.	1.0	2
61	A population-based cohort study defines prognoses in severe chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1217-1226.	2.6	26
62	Extracellular fluid management and hypertension in urban dwelling versus rural dwelling hemodialysis patients. <i>Journal of Nephrology</i> , 2018, 31, 103-110.	0.9	1
63	Central venous catheters for chronic hemodialysis: Is â€œlast choiceâ€“ never the â€œright choiceâ€“?. <i>Seminars in Dialysis</i> , 2018, 31, 3-10.	0.7	9
64	Comparison of Patient Survival Between Hemodialysis and Peritoneal Dialysis Among Patients Eligible for BothÂModalities. <i>American Journal of Kidney Diseases</i> , 2018, 71, 344-351.	2.1	126
65	Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. <i>JAMA Network Open</i> , 2018, 1, e184852.	2.8	181
66	Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. <i>Transplantation Direct</i> , 2018, 4, e389.	0.8	12
67	Trends in Biopsy-Based Diagnosis of Kidney Disease: A Population Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811879969.	0.6	25
68	Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not. <i>Kidney International</i> , 2018, 94, 582-588.	2.6	26
69	Selection of peritoneal dialysis among older eligible patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw367.	0.4	13
70	Emergency Department Use among Patients with CKD: A Population-Based Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 304-314.	2.2	47
71	Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 955-964.	2.2	95
72	Clinical trials in minimal change disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i7-i13.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. <i>BMJ Open</i> , 2017, 7, e013319.	0.8	32
74	Marginal structural models in clinical research: when and how to use them?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii84-ii90.	0.4	75
75	Warfarin Initiation, Atrial Fibrillation, and Kidney Function: A Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. <i>American Journal of Kidney Diseases</i> , 2017, 69, 734-743.	2.1	38
76	Randomized Crossover Trial of Blood Volume Monitoring—Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1831-1840.	2.2	47
77	Multi-Disciplinary Vascular Access Care and Access Outcomes in People Starting Hemodialysis Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1991-1999.	2.2	16
78	Ofatumumab-associated acute pneumonitis: Not new but still the first case. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00267.	1.1	7
79	Are Female Applicants Rated Higher Than Males on the Multiple Mini-Interview? Findings From the University of Calgary. <i>Academic Medicine</i> , 2017, 92, 841-846.	0.8	23
80	The biobank for the molecular classification of kidney disease: research translation and precision medicine in nephrology. <i>BMC Nephrology</i> , 2017, 18, 252.	0.8	20
81	Risk, Predictors, and Outcomes of Acute Kidney Injury in Patients Admitted to Intensive Care Units in Egypt. <i>Scientific Reports</i> , 2017, 7, 17163.	1.6	27
82	Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1787.	3.8	112
83	The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 613-620.	3.0	73
84	Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis. <i>Transplantation</i> , 2016, 100, 1955-1962.	0.5	38
85	Pre-emptive correction for haemodialysis arteriovenous access stenosis. <i>The Cochrane Library</i> , 2016, , CD010709.	1.5	12
86	Citrate vs. acetate dialysate on intradialytic heparin dose: A double blind randomized crossover study. <i>Hemodialysis International</i> , 2016, 20, 537-547.	0.4	6
87	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
88	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2016, , .	1.5	4
89	ACCESS HD pilot: A randomised feasibility trial Comparing Catheters with fistulas in Elderly patients Starting haemodialysis. <i>BMJ Open</i> , 2016, 6, e013081.	0.8	19
90	Patient Education and Peritoneal Dialysis Modality Selection: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 422-433.	2.1	77

#	ARTICLE	IF	CITATIONS
91	Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2022-2031.	2.2	30
92	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89
93	Incidence of melanoma in organ transplant recipients in Alberta, Canada. <i>Clinical Transplantation</i> , 2016, 30, 1271-1275.	0.8	7
94	Atrial fibrillation and chronic kidney disease: struggling through thick and thin: Table 1. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw378.	0.4	10
95	Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1146-1148.	1.1	10
96	Effects of longitudinal changes in Charlson comorbidity on prognostic survival model performance among newly diagnosed patients with hypertension. <i>BMC Health Services Research</i> , 2016, 16, 671.	0.9	1
97	Willingness to Participate in a Randomized Trial Comparing Catheters to Fistulas for Vascular Access in Incident Hemodialysis Patients: An International Survey of Nephrologists. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 125.	0.6	3
98	The attributes of an effective teacher differ between the classroom and the clinical setting. <i>Advances in Health Sciences Education</i> , 2016, 21, 833-840.	1.7	3
99	Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2016, 67, 446-460.	2.1	56
100	Calculating the Rate of Senescence From Mortality Data: An Analysis of Data From the ERA-EDTA Registry. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 468-474.	1.7	5
101	Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 710-720.	2.2	70
102	Regulatory T cells and minimal change nephropathy: in the midst of a complex network. <i>Clinical and Experimental Immunology</i> , 2016, 183, 166-174.	1.1	58
103	Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 120-128.	0.4	132
104	Regulatory T Cells and Oxidative Stress in Minimal Change Nephropathy. , 2016, , 93-103.		0
105	A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome. <i>PLoS ONE</i> , 2015, 10, e0138343.	1.1	16
106	Barriers to Adopting a Fistula-First Policy in Europe: An International Survey among National Experts. <i>Journal of Vascular Access</i> , 2015, 16, 113-119.	0.5	20
107	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. <i>Kidney International</i> , 2015, 87, 1223-1229.	2.6	28
108	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	2.1	52

#	ARTICLE	IF	CITATIONS
109	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1028-1037.	0.4	81
110	The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. <i>BMJ, The</i> , 2015, 350, h246-h246.	3.0	125
111	Rituximab in Children with Steroid-Dependent Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2259-2266.	3.0	156
112	The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial. <i>BMC Nephrology</i> , 2015, 16, 147.	0.8	6
113	Analyzing hospitalization data: potential limitations of Poisson regression. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1244-1249.	0.4	62
114	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1905-1924.	3.0	58
115	A nephrology guide to reading and using systematic reviews of observational studies. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1615-1621.	0.4	1
116	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2015, 1281, 3-18.	0.4	4
117	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2015, 1281, 93-131.	0.4	2
118	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2015, 1281, 71-92.	0.4	0
119	Internal Medicine residents use heuristics to estimate disease probability. <i>Canadian Medical Education Journal</i> , 2015, 6, e71-7.	0.3	1
120	Kidney Function, Albuminuria and Life Expectancy. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 33.	0.6	13
121	Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. <i>Cmaj</i> , 2014, 186, 112-117.	0.9	117
122	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2483-2498.	3.0	112
123	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014, 86, 1244-1252.	2.6	91
124	An Economic Evaluation of rt-PA Locking Solution in Dialysis Catheters. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2887-2895.	3.0	27
125	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1956-1964.	0.4	79
126	Fistula-first and catheter-last: fading certainties and growing doubts. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 727-730.	0.4	40

#	ARTICLE	IF	CITATIONS
127	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv15-iv25.	0.4	180
128	Ultrafiltration biofeedback guided by blood volume monitoring to reduce intradialytic hypotensive episodes in hemodialysis: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 483.	0.7	9
129	Impact of Modality Choice on Rates of Hospitalization in Patients Eligible for Both Peritoneal Dialysis and Hemodialysis. <i>Peritoneal Dialysis International</i> , 2014, 34, 41-48.	1.1	33
130	Predictors of Treatment with Mastectomy, Use of Sentinel Lymph Node Biopsy and Upstaging to Invasive Cancer in Patients Diagnosed with Breast Ductal Carcinoma In situ (DCIS) on Core Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 66-73.	0.7	34
131	Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program. <i>Canadian Journal of Cardiology</i> , 2014, 30, 16-21.	0.8	19
132	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 485-501.	0.8	221
133	Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. <i>Gut</i> , 2014, 63, 552-558.	6.1	154
134	Risk of death following kidney allograft failure: a systematic review and meta-analysis of cohort studies. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1778-1786.	0.4	37
135	Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv1-iv8.	0.4	65
136	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	9.4	505
137	Temporal Risk Profile for Infectious and Noninfectious Complications of Hemodialysis Access. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1668-1677.	3.0	91
138	Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. <i>Diabetologia</i> , 2013, 56, 1949-1957.	2.9	35
139	Patterns of engagement with the health care system and risk of subsequent hospitalization amongst patients with diabetes. <i>BMC Health Services Research</i> , 2013, 13, 399.	0.9	8
140	Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 112-122.	2.1	81
141	Association of a Change in Erythropoiesis-Stimulating Agent Dose During Hospitalization and Subsequent Hemoglobin Levels and Transfusions in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2013, 62, 947-952.	2.1	2
142	Proteinuria and Life Expectancy. <i>American Journal of Kidney Diseases</i> , 2013, 61, 646-648.	2.1	21
143	Associations between Hemodialysis Access Type and Clinical Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 465-473.	3.0	560
144	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, 528-542.	0.8	163

#	ARTICLE	IF	CITATIONS
145	Hemodialysis prescription education decreases intradialytic hypotension. <i>Journal of Nephrology</i> , 2013, 26, 315-322.	0.9	8
146	Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. <i>Kidney International</i> , 2013, 84, 1025-1033.	2.6	109
147	Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. <i>Diabetes Care</i> , 2013, 36, 1172-1180.	4.3	63
148	Urine Creatinine Excretion and Clinical Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1877-1883.	2.2	43
149	Factors Associated with Initiation of Chronic Renal Replacement Therapy for Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1327-1335.	2.2	13
150	Timing and Outcome of Renal Replacement Therapy in Patients with Congenital Malformations of the Kidney and Urinary Tract. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 67-74.	2.2	174
151	Proteinuria and Rate of Change in Kidney Function in a Community-Based Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1661-1667.	3.0	97
152	Galectin-3 and New-Onset CKD: Marker or Mediator?. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1342-1344.	3.0	9
153	Estimated GFR and Fracture Risk. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1367-1376.	2.2	43
154	Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients. <i>PLoS ONE</i> , 2013, 8, e72694.	1.1	35
155	Association between perceived unmet health care needs and risk of adverse health outcomes among patients with chronic medical conditions. <i>Open Medicine</i> , 2013, 7, e21-30.	1.5	13
156	Outcomes of Male Patients with Alport Syndrome Undergoing Renal Replacement Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1969-1976.	2.2	56
157	Chronic kidney disease and life expectancy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3182-3186.	0.4	103
158	The Duke Activity Status Index in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 573-580.	2.2	31
159	Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1117-1124.	3.0	144
160	Lifetime Risk of ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1569-1578.	3.0	72
161	The effect of timing of the first kidney transplantation on survival in children initiating renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1256-1264.	0.4	18
162	Validating a case definition for chronic kidney disease using administrative data. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1826-1831.	0.4	68

#	ARTICLE	IF	CITATIONS
163	Optimizing the dialysate calcium concentration in bicarbonate haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2489-2496.	0.4	31
164	Time trend in access to the waiting list and renal transplantation: a comparison of four European countries. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3621-3631.	0.4	31
165	Association between pre-transplant dialysis modality and patient and graft survival after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4473-4480.	0.4	26
166	Rates of Treated and Untreated Kidney Failure in Older vs Younger Adults. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2507-15.	3.8	128
167	Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2484-2493.	1.9	48
168	Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1394-1400.	2.2	123
169	Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. <i>Journal of Nephrology</i> , 2012, 25, 1016-1022.	0.9	17
170	Association between chronic conditions and perceived unmet health care needs. <i>Open Medicine</i> , 2012, 6, e48-58.	1.5	21
171	Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. <i>Journal of Proteomics</i> , 2011, 74, 2008-2017.	1.2	101
172	Genome-wide association study identifies susceptibility loci for IgA nephropathy. <i>Nature Genetics</i> , 2011, 43, 321-327.	9.4	528
173	Morphometric and Biological Characterization of Biofilm in Tunneled Hemodialysis Catheters. <i>American Journal of Kidney Diseases</i> , 2011, 57, 449-455.	2.1	31
174	Validation of a case definition to define chronic dialysis using outpatient administrative data. <i>BMC Medical Research Methodology</i> , 2011, 11, 25.	1.4	38
175	Associations Between Acute Kidney Injury and Cardiovascular and Renal Outcomes After Coronary Angiography. <i>Circulation</i> , 2011, 123, 409-416.	1.6	309
176	Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2940-2947.	0.4	96
177	New insights into membranous glomerulonephritis: from bench to bedside. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2428-2430.	0.4	18
178	Cardiovascular and Noncardiovascular Mortality among Men and Women Starting Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1722-1730.	2.2	117
179	Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1308-1315.	2.2	180
180	Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2010, 153, 23.	2.0	297

#	ARTICLE	IF	CITATIONS
181	Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 506-512.	2.1	53
182	Modeling Survival of Arteriovenous Accesses for Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1243-1248.	2.2	11
183	Technique Failure in Peritoneal Dialysis Patients: Insights and Challenges. <i>Peritoneal Dialysis International</i> , 2010, 30, 161-162.	1.1	12
184	Nephrology Visits and Health Care Resource Use Before and After Reporting Estimated Glomerular Filtration Rate. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1151.	3.8	141
185	Lack of Association between Dialysis Modality and Outcomes in Atheroembolic Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 454-459.	2.2	10
186	Atheroembolic renal disease. <i>Lancet, The</i> , 2010, 375, 1650-1660.	6.3	156
187	A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 324-324.	0.6	0
188	Clinical Features and Long-Term Outcome of Nephrotic Syndrome Associated with Heterozygous NPHS1 and NPHS2 Mutations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1065-1072.	2.2	38
189	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1052-1061.	2.1	64
190	Overview of the Alberta Kidney Disease Network. <i>BMC Nephrology</i> , 2009, 10, 30.	0.8	221
191	Controversies and Concerns in Hemodialysis – Series Editor: Marcello Tonelli: What’s Next After <i><i>Fistula First</i></i> : Is an Arteriovenous Graft or Central Venous Catheter Preferable When an Arteriovenous Fistula Is Not Possible?. <i>Seminars in Dialysis</i> , 2009, 22, 539-544.	0.7	15
192	Renal outcome in patients with congenital anomalies of the kidney and urinary tract. <i>Kidney International</i> , 2009, 76, 528-533.	2.6	309
193	Vitamin D levels and patient outcome in chronic kidney disease. <i>Kidney International</i> , 2009, 75, 88-95.	2.6	384
194	Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. <i>Canadian Journal of Surgery</i> , 2009, 52, 92-7.	0.5	23
195	Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. <i>Journal of Nephrology</i> , 2009, 22, 152-9.	0.9	30
196	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2008, 473, 1-17.	0.4	10
197	Clinical research of kidney diseases V: extended analytic models. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1484-1492.	0.4	8
198	Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. <i>Kidney International</i> , 2008, 73, 95-101.	2.6	21

#	ARTICLE	IF	CITATIONS
199	Modeling Longitudinal Data, II: Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2008, 473, 61-94.	0.4	4
200	Modeling Longitudinal Data, I: Principles of Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2008, 473, 39-60.	0.4	0
201	Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. <i>Journal of Nephrology</i> , 2008, 21, 861-70.	0.9	15
202	Clinical research of kidney diseases 1: researchable questions and valid answers. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2459-2468.	0.4	3
203	Clinical research of kidney diseases II: problems of study design. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2785-2794.	0.4	15
204	Clinical research of kidney diseases III: Principles of regression and modelling. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3422-3430.	0.4	15
205	Clinical research of kidney diseases 1: researchable questions and valid answers. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3681-3690.	0.4	9
206	Clinical research of kidney diseases IV: standard regression models. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 475-482.	0.4	8
207	The Challenge of Diagnosing Atheroembolic Renal Disease. <i>Circulation</i> , 2007, 116, 298-304.	1.6	142
208	Pregnancy in CKD Stages 3 to 5: Fetal and Maternal Outcomes. <i>American Journal of Kidney Diseases</i> , 2007, 49, 753-762.	2.1	238
209	Clinical epidemiology of arteriovenous fistula in 2007. <i>Journal of Nephrology</i> , 2007, 20, 141-9.	0.9	29
210	Biology of arteriovenous fistula failure. <i>Journal of Nephrology</i> , 2007, 20, 150-63.	0.9	163
211	Autogenous arteriovenous fistula options. <i>Journal of Nephrology</i> , 2007, 20, 288-98.	0.9	26
212	Vascular mapping techniques: advantages and disadvantages. <i>Journal of Nephrology</i> , 2007, 20, 299-303.	0.9	19
213	Surgical salvage of the autogenous arteriovenous fistula (AVF). <i>Journal of Nephrology</i> , 2007, 20, 388-98.	0.9	35
214	Interventional nephrology: from episodic to coordinated vascular access care. <i>Journal of Nephrology</i> , 2007, 20, 399-405.	0.9	27
215	The native arteriovenous fistula in 2007. Surveillance and monitoring. <i>Journal of Nephrology</i> , 2007, 20, 656-67.	0.9	41
216	The native arteriovenous fistula in 2007. Research needs. <i>Journal of Nephrology</i> , 2007, 20, 668-73.	0.9	6

#	ARTICLE	IF	CITATIONS
217	How to improve dialysis adequacy in patients with vascular access problems. Journal of Vascular Access, 2006, 7, 53-59.	0.5	16
218	IgA Nephropathy: The Presence of Familial Disease Does Not Confer an Increased Risk for Progression. American Journal of Kidney Diseases, 2006, 47, 761-769.	2.1	23
219	More Infiltration in Less Mature Fistulae?. American Journal of Kidney Diseases, 2006, 48, 181.	2.1	0
220	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 710-717.	2.2	67
221	American Society of Diagnostic and Interventional Nephrology Section Editor: Stephen Ash: Arteriovenous Fistula Surgery: An American Perspective from Italy. Seminars in Dialysis, 2005, 18, 542-549.	0.7	6
222	Fistula maturation: doesn't time matter at all?. Nephrology Dialysis Transplantation, 2005, 20, 684-687.	0.4	35
223	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. Journal of the American Society of Nephrology: JASN, 2005, 16, 2449-2455.	3.0	352
224	The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrology Dialysis Transplantation, 2005, 20, 147-154.	0.4	177
225	Acute renal failure after right nephrectomy for spontaneous rupture and left renal vein ligation. Clinical Nephrology, 2005, 64, 167-170.	0.4	0
226	Factors associated with unsuccessful utilization and early failure of the arterio-venous fistula for hemodialysis. Journal of Nephrology, 2005, 18, 188-96.	0.9	26
227	Cardiovascular Comorbidity and Late Referral Impact Arteriovenous Fistula Survival: A Prospective Multicenter Study. Journal of the American Society of Nephrology: JASN, 2004, 15, 204-209.	3.0	95
228	Predictors of Renal and Patient Outcomes in Atheroembolic Renal Disease: A Prospective Study. Journal of the American Society of Nephrology: JASN, 2003, 14, 1584-1590.	3.0	134
229	The choice of the dialysate calcium concentration in the management of patients on haemodialysis and haemodiafiltration. Nephrology Dialysis Transplantation, 2003, 18, 37vii-40.	0.4	26
230	Structured pre-dialysis programs: more than just timely referral?. Journal of Nephrology, 2003, 16, 862-9.	0.9	25
231	Multidisciplinary chronic kidney disease management improves survival on dialysis. Journal of Nephrology, 2003, 16, 870-7.	0.9	36
232	Vascular access surgery managed by renal physicians: The choice of native arteriovenous fistulas for hemodialysis. American Journal of Kidney Diseases, 2002, 40, 1264-1276.	2.1	77
233	Early Failure Rates of Arteriovenous Fistulas for Hemodialysis: Evaluation of Six-Year Activity. Journal of Vascular Access, 2001, 2, 154-160.	0.5	3
234	Factors Influencing Permanent Catheter Performance. Journal of Vascular Access, 2001, 2, 106-109.	0.5	27

#	ARTICLE	IF	CITATIONS
235	Dialysis Prescription in Elderly Hemodialysis Patients. Journal of Vascular Access, 2000, 1, 139-143.	0.5	3
236	Ofatumumab or Rituximab for Children with Steroid- and Calcineurin Inhibitor -Dependent Nephrotic Syndrome - <i>A Superiority Randomized Controlled Trial (OFA2)</i>. SSRN Electronic Journal, 0, , .	0.4	0